Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00168831 · ClinicalTrials.gov registry record · Phase 3
Tiotropium / Respimat One-Year Study
A Phase 3 study of Pulmonary Disease, Chronic Obstructive, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,007
- Enrollment target
- 20
- Study locations
NCT00168831 is a Phase 3 study of Pulmonary Disease, Chronic Obstructive that has completed, run by Boehringer Ingelheim. The registered enrollment target is 1,007 participants, roughly in line with the 1,030-participant average among 74 other Pulmonary Disease, Chronic Obstructive trials with a reported enrollment target. The trial reports 20 study locations across 13 states.
The verdict
NCT00168831, a Phase 3 study of Pulmonary Disease, Chronic Obstructive, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,007 participants
- Enrollment target
- 20
- Study locations
Study Summary
To evaluate the long term effects of treatment with two doses of Tiotropium delivered by the Respimat inhaler in patients with COPD.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Tiotropium Inhalation Solution
Study Locations (20)
Other
- Boehringer Ingelheim Investigational Site - Innsbruck
- Boehringer Ingelheim Investigational Site - Mittersill
- Boehringer Ingelheim Investigational Site - Schwechat
- Baumgartner Hohe Otto Wagner Spital Wien - Vienna
- Boehringer Ingelheim Investigational Site - Vienna
California
- Boehringer Ingelheim Investigational Site - La Jolla
- Boehringer Ingelheim Investigational Site - Long Beach
- Boehringer Ingelheim Investigational Site - San Luis Obispo
Florida
- Boehringer Ingelheim Investigational Site - Gainesville
- Boehringer Ingelheim Investigational Site - Hallandale
Alabama
- Boehringer Ingelheim Investigational Site - Birmingham
Illinois
- Boehringer Ingelheim Investigational Site - Hines
Missouri
- Boehringer Ingelheim Investigational Site - Chesterfield
New York
- Boehringer Ingelheim Investigational Site - Bay Shore
South Carolina
- Boehringer Ingelheim Investigational Site - Charleston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,007 participants |
| Start Date | 2003-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00168831
The ClinicalTrials.gov registry entry for NCT00168831 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,007 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 1,030-participant average among 74 other Pulmonary Disease, Chronic Obstructive trials with a reported enrollment target. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Pulmonary Disease, Chronic Obstructive appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00168831 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Other, California, Florida.
Frequently Asked Questions
What is clinical trial NCT00168831 about?
NCT00168831 is a clinical study titled "Tiotropium / Respimat One-Year Study". To evaluate the long term effects of treatment with two doses of Tiotropium delivered by the Respimat inhaler in patients with COPD.
What is the current status of trial NCT00168831?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,007 participants. The study started on 2003-02.
What conditions does trial NCT00168831 study?
This clinical trial studies the following conditions: Pulmonary Disease, Chronic Obstructive.
What interventions are being tested in trial NCT00168831?
The interventions under investigation include: Placebo (OTHER), Tiotropium Inhalation Solution (DRUG).
Who is sponsoring clinical trial NCT00168831?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00168831 being conducted?
This trial has 20 study locations across Alabama, California, Florida, Illinois, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pulmonary Disease, Chronic Obstructive
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)
RECRUITING · Phase 3
-
eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation
RECRUITING · Phase 3
-
Trial to Determine Effective Aspirin Dose in COPD
RECRUITING · Phase 3
-
Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA -1)
RECRUITING · Phase 3
-
An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444.Study B
COMPLETED · Phase 3
-
A 12-week Study to Evaluate the Efficacy and Safety of Umeclidinium Compared With Tiotropium in Subjects With Chronic Obstructive Pulmonary Disease
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.